Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A concise checklist to verify inputs, validate assumptions, and confirm your zero based budget remains aligned with priorities.
17,617 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Curious about SoundHound AI's future? This in-depth guide lays out five-year scenarios, key drivers, and concrete tip...
Beyond Meat faces a double headwind: a tepid forecast and a crowded protein-drink market. Investors are reeling as re...
SpaceX is positioning Starship V3 as the backbone of an IPO that could redefine private markets. Analysts say the nex...
In May, nano nuclear energy powered stocks surged as collaborations with data centers and regulatory progress lifted ...
SpaceX is entering the IPO spotlight, but valuing a space, AI, and satellite powerhouse is unique. This guide breaks ...
The GTLB story has investors buzzing about whether a rebound is ahead. Even as revenue trends stay strong, the stock ...
When a chief operating officer discloses a large stock sale, it can raise questions for investors. This guide explain...
SpaceX IPO chatter has investors buzzing about windfalls for insiders and thousands of workers with equity. This repo...
With the 2026 World Cup in North America on the horizon, per-player earnings from prize money could swing widely depe...
As digital transformation accelerates, two distinct paths emerge: AppLovin's AI-powered ad tech vs. Twilio's global c...
A stock dip can be a doorway to opportunity if you approach it with a solid plan. This guide explains how to evaluate...